Qiagen NV traded at 36.34 this Friday July 24th, decreasing 0.24 or 0.66 percent since the previous trading session. Looking back, over the last four weeks, Qiagen NV lost 5.26 percent. Over the last 12 months, its price fell by 17.18 percent. Looking ahead, we forecast Qiagen NV to be priced at 35.16 by the end of this quarter and at 32.85 in one year, according to Trading Economics global macro models projections and analysts expectations.
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.